Quet

Quick links to important sections

Quet

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quet

What is Quet? Overview

Property Description
Active Ingredient Quetiapine Fumarate
Form Oral tablet (Immediate-Release and Extended-Release)
Pharmacological Class Atypical Antipsychotic (Second-Generation Antipsychotic)
General Purpose Stabilizing mood and thought processes
Origin Synthetic (Dibenzothiazepine derivative)
Prescribing Status Prescription-Only (Rx)

What is Quetiapine and What Class of Medicine is Quet?

Quet is a brand name for the generic drug quetiapine, a prescription-only medicine that is officially classified as an atypical antipsychotic. This class is also known as a second-generation antipsychotic, signifying that the medicine acts by balancing the activity of chemical messengers in the brain.

The core substance is quetiapine fumarate, which is the International Nonproprietary Name (INN) for the active pharmaceutical ingredient. Chemically, it is a synthetic compound derived from the dibenzothiazepine structure. This pharmacological differentiation is clinically recognized for its potent action on both serotonin and dopamine systems. This means the compound helps to stabilize the chemical environment in the brain responsible for mood and perception.

Form and General Purpose of Quet

Quetiapine is manufactured as a solid oral tablet designed for oral administration, containing only the active ingredient and necessary excipients. A key differentiating feature is that the active drug, quetiapine fumarate, is presented in two main versions: the immediate-release (IR) formulation and the extended-release (XR) formulation.

The general purpose of this medication is to help stabilize profound disruptions in mental health. By modulating neurochemical activity, quetiapine supports the brain's natural ability to manage severe mood fluctuations and episodes of disorganized thinking. Quetiapine is used to manage certain conditions by helping to restore balance to brain chemicals, which is the foundation of its therapeutic efficacy.

Regulatory References

  1. MedlinePlus Drug Information on Quetiapine

What side effects are possible with Quet?

Possible Side Effects and Safety Information

The safety profile of Quet (quetiapine fumarate) is characterized by documented adverse reactions categorized by their frequency and the physiological systems affected, as outlined in official regulatory documents. These effects range from frequently observed non-serious events to rare but clinically significant adverse reactions.


Adverse Reaction Classification

Classification Representative Side Effects (Documented)
Very Common Somnolence (drowsiness), Dizziness, Dry Mouth, Weight Gain, Decreased Hemoglobin.
Common Orthostatic Hypotension, Tachycardia, Constipation, Dyspepsia, Fatigue, Increased Appetite.
Uncommon Seizures, Hypersensitivity, Severe Neutropenia, Dysphagia (difficulty swallowing).
Rare Neuroleptic Malignant Syndrome (NMS), Agranulocytosis, Intestinal Obstruction.

Systemic Safety Concerns and Serious Adverse Reactions

The official labeling notes that adverse reactions primarily involve the Nervous System, Metabolism and Nutrition, and Cardiovascular System. Serious adverse reactions listed in regulatory documents include Neuroleptic Malignant Syndrome (NMS) and significant Metabolic Changes such as hyperglycemia, which can lead to complications like ketoacidosis. Hematological risks, including Neutropenia and Agranulocytosis, are also documented safety concerns.

Safety patterns tied to duration include Orthostatic Hypotension, which is often more common during the initial dose titration period. Conversely, conditions like Tardive Dyskinesia are associated with prolonged use. The label notes that abrupt cessation may result in Discontinuation Syndrome symptoms.

Population and Monitoring Notes

Specific warnings are documented for Elderly Patients with Dementia-Related Psychosis, citing an increased risk of death and cerebrovascular adverse events. The regulatory constraints mandate periodic monitoring of fasting blood glucose, blood lipids, and weight throughout treatment. Additionally, a lens examination is officially recommended when initiating treatment and periodically thereafter.

Overdose and Emergency Response

The official overdose profile for Quet (Quetiapine Fumarate) describes a range of manifestations primarily affecting the central nervous system and cardiovascular function. Documented overdose presentations typically include pronounced somnolence, sedation, tachycardia (fast heart rate), and hypotension (low blood pressure).

Severe intoxication can progress to profound CNS depression, coma, and respiratory depression, with seizures and QT prolongation (a cardiac electrical abnormality) also reported. Fatal outcomes have occurred, particularly when Quetiapine was taken in very high doses or with other co-ingested medicines. Elderly patients with pre-existing severe cardiovascular disease are officially noted as a population potentially at increased risk for severe effects.

Given the potential for life-threatening complications, official regulatory information mandates that immediate medical attention must be sought for any suspected overdose. Management is strictly supportive and symptomatic, as no specific antidote is known. Hospital-based treatment involves establishing and maintaining a patent airway and continuous ECG monitoring to evaluate cardiac risk. For treating severe hypotension, official guidance advises avoiding the use of epinephrine and dopamine, which may worsen low blood pressure.

Therapeutic Uses of Quet

What Quet Treats: Main Uses and Benefits

The medication is applied in clinical settings that involve profound thought disturbances characteristic of Schizophrenia, such as hallucinations, delusions, and disorganized thinking. This use generally assists with maintaining stability of perception, and may assist with easing the overall symptom load and managing distressing manifestations.

Quet is also commonly used across conditions characterized by episodic or fluctuating symptom patterns. These therapeutic domains include the management of Schizophrenia, acute manic and depressive episodes associated with Bipolar Disorder, and as an adjunctive treatment to support existing antidepressant therapy for Major Depressive Disorder. Its therapeutic benefit is relevant for easing symptoms that interfere with daily comfort and helps maintain a sense of stability when symptoms are more noticeable, supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Symptomatic Management for Mood Fluctuations
This therapeutic context is relevant for easing symptoms that cluster into patterns requiring supportive management, specifically the high energy of mania and the low mood of bipolar depression.

Eligibility and Restrictions for Use

Who Can and Cannot Use Quet?

Eligibility for using Quet (quetiapine fumarate) is strictly determined by regulatory authorities based on age, physiological status, and the presence of specific comorbidities or concurrent medications.


Contraindicated Populations (Must Not Use)

Classification Population
Absolute Contraindication Patients with known hypersensitivity to quetiapine or any component of the formulation.
Age/Comorbidity Exclusion Elderly patients with dementia-related psychosis.
Drug Interaction Exclusion Patients taking concomitant strong CYP3A4 inhibitors (e.g., certain antifungals, HIV-protease inhibitors).

Age and Conditional Use Rules

Population Regulatory Status
Adults (≥18 years) Approved for all labeled uses.
Children (Under 10) Not approved for any indication.
Adolescents (10–17) Approved only for Schizophrenia (13–17) and Bipolar Mania (10–17); not established for depression.
Hepatic Impairment Restricted use; requires caution and a lower starting dose.

Pregnancy and Lactation: Use during pregnancy is conditional; it is allowed only if the potential benefit justifies the potential risk. Use while breastfeeding is not recommended by regulatory bodies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Quetiapine (Quet) has formally documented interaction patterns governed primarily by its metabolism and pharmacodynamic effects, as outlined in official regulatory documents.

Pharmacokinetic and Metabolic Interactions

Quetiapine is metabolized mainly by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with strong CYP3A4 modulators results in significantly altered drug exposure:

  • Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, nefazodone) decrease quetiapine clearance, causing a marked increase in plasma concentration. This combination is formally classified as contraindicated in some regulatory regions.
  • Strong CYP3A4 Inducers (e.g., phenytoin, rifampin, St. John's wort) increase clearance, leading to a significant reduction in plasma concentration.

Pharmacodynamic and Substance Interactions

  • Centrally Acting Drugs and Alcohol: Co-administration with other CNS depressants (including alcohol and antihistamines) may result in additive CNS effects, such as increased somnolence, as documented in regulatory labeling.
  • Other Agents: Quetiapine has officially documented additive effects with antihypertensive agents (leading to additive hypotension) and anticholinergic/antimuscarinic drugs.

Administration Constraints

  • Food Effect: The extended-release (XR) formulation has a documented interaction with food. The tablet must be taken either without food or with a light meal (300 calories or less) to avoid a significant, documented increase in drug exposure.

Mechanism of Action

Molecular Target and Allosteric Modulation

Quet acts as an allosteric modulator, selectively binding to the receptor R Quet expressed on the surface of pre-osteoclasts.


Intracellular Signaling and Pathway Cascade

This binding event initiates an intracellular signaling cascade, involving the activation of protein kinase C ( PKC) and the subsequent phosphorylation of the nuclear factor NFATc1. This cascade alters the expression ratio of RANKL/OPG within the bone microenvironment.


Cellular and Physiological Consequence

Quet modulates the activity of osteoblasts and osteoclasts, influencing bone turnover markers. This modulation influences the remodeling of the bone matrix and reduces the rate of bone resorption, leading to a net positive bone mineral balance.

Dosage and Administration Information

The only approved method for taking Quet is oral administration via tablet. The medication is manufactured in two distinct forms: the Immediate-Release (IR) tablet, which is typically taken in divided doses twice daily, and the Extended-Release (XR) tablet, which is designed for once-daily administration, preferably in the evening.

Use of the medicine always begins with a low starting dose that is systematically titrated (gradually increased) over the first few days of treatment. The final established adult maintenance dose ranges from 150 mg/day to a maximum of 800 mg/day. For example, the typical maintenance range for schizophrenia can be 150 mg/day to 750 mg/day, while the maximum dose for bipolar depression is 300 mg/day.

Administration of the IR tablets is flexible and may occur with or without food. In contrast, the XR tablets must be taken without food or with only a light meal (approximately 300 calories) to maintain the intended release profile. Furthermore, the XR tablet must be swallowed whole and is restricted from being split, chewed, or crushed.

Special dosing considerations apply to certain groups. Older adults and patients with hepatic (liver) impairment require a lower starting dose (e.g., 25 mg to 50 mg daily) and a significantly slower rate of titration compared to younger, unimpaired adults. If XR treatment is discontinued for more than one week, re-titration is necessary.

Recent Clinical Evidence

Research evidence / Overview of Studies for Quet

Research evidence for Quet was collected in studies focused on Schizophrenia, where multiple short-term, placebo-controlled Randomized Controlled Trials (RCTs) were conducted. This research explored how symptoms change over time in adults experiencing acute episodes, as well as in adolescents. Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in short-term efficacy measures. For long-term use, evidence often relies on open-label extension studies and naturalistic observations, which track symptom patterns over extended intervals.

The clinical research focused on Bipolar Disorder was detailed in separate studies for acute manic episodes and acute depressive episodes. For acute mania, Quet was evaluated as a single treatment and in adjunctive studies alongside other medications. Findings indicate measured differences in symptom severity scores between the Quet group and the placebo group in these short-term trials. Similarly, controlled trials for acute depressive episodes also highlighted changes measured in depressive symptom scale scores compared to placebo, although the pivotal trials were of short duration.

Quet was also evaluated in studies focused on Major Depressive Disorder as an adjunctive treatment, where research described measured differences during the short-term augmentation period. For most indications, the initial RCTs had limited follow-up durations. Therefore, certainty remains low regarding the long-term evidence base, as controlled, double-blind follow-up for multiple years is not fully established. Key limitations across the evidence include the fact that follow-up durations were limited in many trials, and comparative evidence against all available alternatives is often lacking.

Key Studies & References

  1. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care - NICE Guideline CG185

Frequently Asked Questions (FAQ)

Common questions about Quet (FAQ)

Q: What mental health conditions is Quet specifically approved to treat?

Regulatory documents indicate that this medicine is approved for the treatment of Schizophrenia, Bipolar I Disorder (including manic, mixed, and depressive episodes), and as an adjunctive therapy (a medicine added to another treatment) for Major Depressive Disorder.


Q: Why is Quet sometimes prescribed for conditions besides psychosis?

Official labeling limits approval to specific conditions. However, the medicine has been studied or used in clinical settings for other conditions, such as Generalized Anxiety Disorder or difficulty sleeping (insomnia). All prescribing decisions are based on the judgment of a healthcare professional.


Q: How long does it usually take to feel the effects of Quet or see an improvement in mood symptoms?

Clinical trials established efficacy over short periods (e.g., several weeks). Because the dose is gradually increased (titrated) over time, a patient's full clinical response may not become apparent until the stable maintenance dose is achieved.


Q: Does the extended-release version of Quet work differently than the regular tablet?

The two versions differ in administration (once daily vs. twice daily) and food requirements. Additionally, official information suggests that the Extended-Release (XR) formulation may be associated with less sedation when compared to the Immediate-Release (IR) formulation.


Q: Do the side effects of Quet eventually go away after I've been taking it for a while?

Some initial side effects might lessen as the body adjusts to the medicine. However, regulatory warnings note that some significant side effects, such as Tardive Dyskinesia (uncontrolled movements), are considered a risk associated with long-term use of this class of medication.


Q: Can Quet cause dry mouth, and what is the reason for that?

Dry mouth is listed as a commonly reported side effect in official safety documents. This effect is noted in regulatory documents as being linked to the medicine's mechanism of action, specifically its anticholinergic effects.


Q: Are there any long-term health concerns associated with taking Quet?

Long-term health concerns include the potential for Metabolic Changes (such as weight gain, high blood sugar, and increased blood lipid levels) and Tardive Dyskinesia (uncontrolled movements). Official guidance also recommends periodic eye examinations (lens checks) during long-term therapy.


Q: What happens if I forget to take a dose of Quet?

Regulatory instructions state that if a dose is missed, it can be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. If so, the missed dose is typically skipped, and the regular schedule is resumed without doubling the dose.


Q: Is it true that grapefruit juice can be a problem when taking Quet?

Yes. Official regulatory information advises that grapefruit and grapefruit juice are generally avoided while using this medicine. This restriction is advised because grapefruit can increase the concentration of the drug in the bloodstream, which may raise the risk of experiencing side effects.


Q: Does Quet have a high risk of causing movement disorders?

Clinical trial data showed that movement disorders (known as Extrapyramidal Symptoms or EPS) were reported by a low number of participants. However, the risk of Tardive Dyskinesia is a known safety concern for this entire class of medications.


Q: Is Quet considered addictive, or can it cause dependency?

Regulatory sources state that the medicine is not typically regarded as an addictive substance and has a limited potential for misuse. Abuse is usually only noted in individuals with a history of polysubstance use.


Q: What are the official guidelines regarding driving or operating machinery while taking Quet?

Regulatory guidance advises caution regarding activities requiring mental alertness, such as driving or operating heavy machinery. Because drowsiness is a common side effect, official sources recommend determining individual response before engaging in these activities.


Q: Why do some people experience dizziness when standing up on Quet?

Dizziness upon standing is a result of orthostatic hypotension, which is a drop in blood pressure when moving from a sitting or lying position. This is a documented side effect caused by the drug’s mechanism of action, which involves affecting receptors that help regulate blood pressure.


Q: What are the signs of a serious, but rare, side effect like Neuroleptic Malignant Syndrome?

Neuroleptic Malignant Syndrome (NMS) is a rare, but serious, side effect. Clinical manifestations listed in regulatory documents include high fever (hyperpyrexia), severe muscle stiffness or rigidity, and changes in mental state or consciousness. Autonomic instability, such as irregular pulse or blood pressure, may also be evident.


Q: Are there different brand names for the same medicine, Quet?

Yes. Quet is a brand name for the generic medicine quetiapine. The most widely known brand name for this medicine internationally is Seroquel.


Q: How quickly does Quet leave the system if someone stops taking it?

Pharmacokinetic data from regulatory sources provides a measure known as the half-life. The elimination half-life is approximately 7 hours for the main compound and between 9 and 12 hours for the active metabolite, meaning half of the drug is cleared in that time.


Q: Does Quet have effects on sleep patterns, such as vivid dreams or insomnia?

While the medicine can cause somnolence (drowsiness) as a common side effect, official warnings also list trouble sleeping (insomnia) and restlessness as common symptoms if the medicine is abruptly stopped.


Q: Are there any known sexual side effects linked to Quet?

Official sources note potential sexual side effects, including decreased libido and, for men, difficulty in maintaining an erection. These effects are sometimes linked to the medicine's potential to increase levels of the hormone prolactin.


Q: Can Quet impact fertility in men or women?

The medicine may increase prolactin levels in the blood. For women, this may disrupt the menstrual cycle and make it harder to get pregnant. Men may experience decreased libido or other sexual side effects, as noted in official sources.


Q: What are the official warnings about potential suicidal thoughts when starting this medicine?

The FDA label includes a Boxed Warning that this medicine, when used for depression, may increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults. Official guidance states that patients of all ages should be observed closely for clinical worsening.


Q: Can certain medical conditions, like heart problems, prevent someone from taking Quet?

Yes, caution is advised for patients with certain pre-existing conditions. Regulatory sources list specific concerns including heart rhythm problems (such as QT prolongation), hypotension (low blood pressure), or a history of irregular heartbeat.


Q: Does taking Quet mean I will have to be on it for life?

No. The appropriate duration of therapy is variable and depends on the condition being treated and the patient's clinical history. Official guidance suggests treatment can range from at least six months to two years, and for some conditions like bipolar disorder, long-term maintenance is sometimes used.


Q: Why is it important to monitor body temperature when taking Quet?

Monitoring body temperature is important because a high fever (hyperpyrexia) is a clinical sign of the serious, but rare, side effect known as Neuroleptic Malignant Syndrome (NMS).


Q: Does Quet affect the levels of prolactin in the body?

Yes. Official information notes that the drug may cause an increased level of the hormone prolactin (hyperprolactinemia) in the blood. This condition can lead to other effects, such as irregular menstrual periods or other hormonal changes.


Q: What happens if I miss several doses of Quet in a row?

Regulatory instructions state that if the medicine is missed for longer than one week, a prescriber should be contacted before restarting, as the dose may require adjustment (re-titration).


Q: What does official guidance say about weight management while using Quet?

Official guidance mandates periodic monitoring of weight throughout the treatment period due to the documented risk of weight gain and associated metabolic changes. This monitoring allows the prescriber to track potential side effects.


Q: Can Quet cause problems with muscle movement or stiffness?

Yes. Official regulatory information states that the medicine can cause both uncontrolled movements (Tardive Dyskinesia) and severe muscle stiffness or rigidity (a clinical sign of the rare, but serious, side effect Neuroleptic Malignant Syndrome).


Q: What are the signs of discontinuation syndrome if I stop taking Quet?

If the medicine is stopped abruptly, official warnings note a discontinuation syndrome may occur. Common symptoms include nausea, vomiting, trouble sleeping (insomnia), restlessness, and increased sweating. These symptoms typically resolve after a short period.

How should Quet be stored and disposed of?

Quetiapine (Quet) must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, which should be tightly closed, and protected from excessive heat, moisture, and freezing. This protective measure maintains the product's chemical stability as defined by regulatory standards.

Critically, the medication must be stored out of the reach of children. To dispose of unused or expired tablets, use a drug take-back program. If no program is available, the tablets must be mixed with an undesirable substance (such as used coffee grounds or dirt), placed in a sealed container, and thrown into the household trash. The tablets must not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quet found in:

A-Z Index: